Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | LPO | P22079 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | XPO1 | O14980 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17874248 | 0.80 | CA1 (0.41) | MAPTCA1LPOPTGS1SMN1; SMN2 | |
| SCHEMBL21341473 | 0.80 | CA1 (0.48) | MAPTCA1LPOPTGS1SMN1; SMN2 | |
| SCHEMBL3556726 | 0.77 | MAPT (0.47) | MAPTPDE2ASCN8ASCN10ARAB9A | |
| SCHEMBL25065886 | 0.76 | KDM4E (0.46) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL19583320 | 0.74 | GAA (0.46) | MAPTLPOPTGS1SMN1; SMN2KDM4E | |
| SCHEMBL9730639 | 0.74 | XDH (0.38) | MAPTKDM4EHPGDGAAHTT | |
| SCHEMBL20339421 | 0.74 | CES2 (0.35) | MAPTKDM4EHPGDGAAHTT | |
| SCHEMBL18711830 | 0.74 | PDE2A (0.39) | HTTARPDE2ARAB9A | |
| SCHEMBL1700765 | 0.69 | — | — | |
| SCHEMBL30021526 | 0.69 | CYP1A2 (0.57) | MAPTKDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431230-A | Compounds for inhibiting alpha 4 beta 7 integrin | 吉利德科学公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-3873605-B1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES INC (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-114222730-B | Compounds for inhibiting alpha 4 beta 7 integrin | 吉利德科学公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-112969504-B | Compounds for inhibiting alpha 4 beta 7 integrin | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-11578069-B2 | Compounds for inhibition of α4 β7 integrin | GILEAD SCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11578069-B2 | Compounds for inhibition of α4 β7 integrin | GILEAD SCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-4013499-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| CN-114222730-A | Compounds for inhibiting alpha 4 beta 7 integrins | 吉利德科学公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2009030887-A2 | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | WO | disclosed |
| US-6916933-B2 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMAN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1244625-B1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| CN-1196682-C | 4-pyridyl-N-acyl-L-phenylalanine | HOFFMANN LA ROCHE (CH) | 2005-04-13 | — | — | CN | disclosed |
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | KAPLAN GERALD LEWIS (US) | 2004-07-01 | — | — | US | disclosed |
| CN-1402709-A | 4-pyridinyl-N-acyl-L-phenylalanines | HOFFMANN LA ROCHE (CH) | 2003-03-12 | — | — | CN | disclosed |
| EP-1244625-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | KAPLAN GERALD LEWIS (US) | 2002-09-19 | — | — | US | disclosed |
| US-6388084-B1 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMANN-LA ROCHE INC. | 2002-05-14 | — | — | US | disclosed |
| WO-2001042215-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | VCAM1, ICAM1, SELPLG | MAPT 3047/4885CA1 4298/4885LPO 892/4885 |
| US-11578069-B2 | Compounds for inhibition of α4 β7 integrin | ITGB7, ITGB4, ITGA4 | MAPT 3196/4885CA1 3468/4885LPO 3260/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | MAPT 3224/4885CA1 2759/4885LPO 3317/4885 |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | VCAM1, ICAM1, SELPLG | MAPT 3047/4885CA1 4298/4885LPO 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.